Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| Gotu Kola (Centella asiatica) | Modafinil | |
|---|---|---|
| Category | Nootropics | Nootropics |
| Standard Dose | 500-1000 mg/day of standardized extract (35-45% triterpenes) or 750-1500 mg/day of whole herb extract | 100-200 mg once daily (for educational context only — prescription medication in most jurisdictions) |
| Timing | Morning or split morning/afternoon. With or without food. Acute mood effects (alertness, reduced anger) noted within 1 hour of dosing. | Early morning to avoid insomnia; 1 hour before desired peak alertness. With or without food (food slows absorption by ~1 hour but does not reduce bioavailability). Half-life is approximately 12-15 hours. |
| Cycle Duration | Ongoing; traditional use suggests no cycling required. Clinical trials run 2-6 months. | Not typically cycled in clinical use. Some off-label users cycle to maintain sensitivity (5 days on, 2 off; or as-needed use). |
| Evidence Level | moderate_human | strong_human |
Pentacyclic triterpenes — asiaticoside, madecassoside, asiatic acid, and madecassic acid — provide neuroprotection through multiple mechanisms: inhibition of acetylcholinesterase activity and enhancement of cholinergic transmission; reduction of phospholipase A2 (PLA2) activity to attenuate neuroinflammation; protection against beta-amyloid aggregation and tau hyperphosphorylation; and upregulation of BDNF to promote neuronal growth and synaptic plasticity. Asiaticoside enhances collagen synthesis and wound healing, while asiatic acid activates the MAPK/ERK pathway to promote neurite outgrowth.
500-1000 mg/day of standardized extract (35-45% triterpenes) or 750-1500 mg/day of whole herb extract
Morning or split morning/afternoon. With or without food. Acute mood effects (alertness, reduced anger) noted within 1 hour of dosing.
Ongoing; traditional use suggests no cycling required. Clinical trials run 2-6 months.
Atypical eugeroic (wakefulness-promoting agent) that primarily inhibits the dopamine transporter (DAT), increasing extracellular dopamine in the prefrontal cortex and nucleus accumbens. This primary action cascades through multiple systems: indirect activation of orexinergic neurons in the lateral hypothalamus via potentiation of glutamatergic transmission; downstream stimulation of histaminergic neurons in the tuberomammillary nucleus (via orexin-mediated disinhibition of GABAergic inputs); and enhancement of norepinephrine release in the locus coeruleus. The net effect is broad-spectrum arousal without the peripheral sympathomimetic effects of classical stimulants.
100-200 mg once daily (for educational context only — prescription medication in most jurisdictions)
Early morning to avoid insomnia; 1 hour before desired peak alertness. With or without food (food slows absorption by ~1 hour but does not reduce bioavailability). Half-life is approximately 12-15 hours.
Not typically cycled in clinical use. Some off-label users cycle to maintain sensitivity (5 days on, 2 off; or as-needed use).
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →